Royal Jelly Modulates Oxidative Stress and Apoptosis in Liver and Kidneys of Rats Treated with Cisplatin by Karadeniz, Ali et al.
Hindawi Publishing Corporation
Oxidative Medicine and Cellular Longevity
Volume 2011, Article ID 981793, 10 pages
doi:10.1155/2011/981793
Research Article
RoyalJellyModulates Oxidative Stress andApoptosis in
LiverandKidneysofRats TreatedwithCisplatin
Ali Karadeniz,1 Nejdet Simsek,2 EmreKarakus,3 SerapYildirim,4 Adem Kara,2
Ismail Can,2 FikrullahKisa,3 Habib Emre,5 andMehmet Turkeli6
1Department of Physiology, Faculty of Veterinary Medicine, University of Atat¨ urk, 25240 Erzurum, Turkey
2Department of Histology and Embryology, Faculty of Veterinary Medicine, University of Atat¨ urk, 25240 Erzurum, Turkey
3Department of Pharmacology and Toxicology, Faculty of Veterinary Medicine, University of Atat¨ urk, 25240 Erzurum, Turkey
4Department of Physiology, Faculty of Medicine, University of Atat¨ urk, 25240 Erzurum, Turkey
5Department of Nephrology, Faculty of Medicine, University of Y¨ uz¨ unc¨ uY ıl, 65080 Van, Turkey
6Department of Medical Oncology, Faculty of Medicine, University of Atat¨ urk, 25240 Erzurum, Turkey
Correspondence should be addressed to Ali Karadeniz, karadenizali@gmail.com
Received 4 May 2011; Accepted 8 June 2011
Academic Editor: Florian Lang
Copyright © 2011 Ali Karadeniz et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Cisplatin (CDDP) is one of the most active cytotoxic agents in the treatment of cancer and has adverse side eﬀects such as
nephrotoxicity and hepatotoxicity. The present study was designed to determine the eﬀects of royal jelly (RJ) against oxidative
stress caused by CDDP injury of the kidneys and liver, by measuring tissue biochemical and antioxidant parameters and
investigating apoptosis immunohistochemically. Twenty-four Sprague Dawley rats were divided into four groups, group C:
control group received 0.9% saline; group CDDP: injected i.p. with cisplatin (CDDP, 7mgkg−1 body weight i.p., single dose);
group RJ: treated for 15 consecutive days by gavage with RJ (300mg/kg/day); group RJ + CDDP: treated by gavage with RJ 15 days
following a single injection of CDDP. Malondialdehyde (MDA) and glutathione (GSH) levels, glutathione S-transferase (GST),
glutathione peroxidase (GSH-Px), and superoxide dismutase (SOD) activities were determined in liver and kidney homogenates,
and the liver and kidney were also histologically examined. RJ elicited a signiﬁcant protective eﬀect towards liver and kidney by
decreasing the level of lipid peroxidation (MDA), elevating the level of GSH, and increasing the activities of GST, GSH-Px, and
SOD. In the immunohistochemical examinations were observed signiﬁcantly enhanced apoptotic cell numbers and degenerative
changes by cisplatin, but these histological changes were lower in the liver and kidney tissues of RJ + CDDP group. Besides,
treatment with RJ lead to an increase in antiapoptotic activity hepatocytes and tubular epithelium. In conclusion, RJ may be used
in combination with cisplatin in chemotherapy to improve cisplatin-induced oxidative stress parameters and apoptotic activity.
1.Introduction
Cis-Diaminedichloroplatinum(II)(CDDP),commonlyknown
as cisplatin, has been established as a potent chemo-
therapeutic agent administered to treat a variety of cancers
such as ovarian, bladder, testicular, head and neck, and uter-
ine cervix carcinomas [1, 2]. The major dose-limiting side
eﬀectofcisplatinisitsnephrotoxicityandhepatotoxicity,and
nephrotoxicity can result in severe nephropathy leading to
acuterenalfailure.Inseveralstudies,ithadbeendocumented
that injection of cisplatin produced a marked decrease in
renal blood ﬂow and glomerular ﬁltration rate. The alter-
ations in the kidney and liver functions induced by cisplatin
are closely associated with an increase in lipid peroxidation
and reactive oxygen species (ROS) in the tissues [3, 4]. In
addition,cisplatinmayhavesomemechanismsofliverinjury
such as functional and structural mitochondrial damage,
apoptosis, and perturbation in Ca2+ homeostasis [5, 6].
Reactive oxygen species (ROS) such as hydrogen per-
oxide, hydroxyl radical, singlet oxygen, superoxide anion,
and peroxyl radical are formed inside cells by exposure to
several endogenous and exogenous agents, causing damage
to many important biomolecules that have been implicated
inseveraldiseases[7].Theseprooxidantsarekeptincheckby
endogenous antioxidants, but under disease conditions, the
balanceisshiftedinfavorofprooxidants,leadingtooxidative
stress. Excess ROS causes signiﬁcant oxidative damage by
attacking biomolecules such as membrane lipids, DNA, and2 Oxidative Medicine and Cellular Longevity
Table 1: Eﬀects of royal jelly on selected biochemical parameters in rats treated with CDDP.
Parameters Groups
C CDDP RJ RJ + CDDP
ALT (IU/L) 27.45 ± 1.40a 80.50 ± 2.50b 29.50 ± 1.70a 35.85 ± 2.25c
AST (IU/L) 55.8 ± 1.55a 90.80 ± 3.50b 58.8 ± 5.30a 65.75 ± 2.50c
Creatinine (mg/dL) 1.05 ± 0.60a 3.15 ± 0.50b 1.02 ± 0.51a 2.15 ± 0.55c
Diﬀerent superscripts a, b, c in the same row indicate signiﬁcant diﬀerences between groups (n = 6).
P<0.05, means ± S.E.M. C: Control, RJ: royal jelly, CDDP: cisplatin.
proteins in cells [8]. The oxidative stress is associated with
many disease states including neurological diseases such as
Alzheimer’s brains and Parkinson’s disease, chronic heart
disease, and kidney and liver diseases [9]. Endogenous
antioxidants such as reduced glutathione (GSH), glutathione
peroxidase(GSH-PX),superoxidedismutase(SOD),catalase
(CAT) are compounds that act as free radical scavengers.
These antioxidants are electron donors and react with the
f r e er a d i c a l st of o r mh a r m l e s sp r o d u c t ss u c ha sw a t e r .
Therefore, antioxidants protect against oxidative stress and
prevent damage to cells [10].
Some natural products, such as lycopen [11], grape seed
extract [12], green tea [13], and caﬀeic acid phenethyl ester
[14], are demonstrated to have a protective role against
cisplatin-induced kidney and liver oxidative damages.
Hence, there has been considerable interest in role of
naturally originated agents for the treatment of kidney and
liver diseases. Recently,royal jelly (RJ) has received particular
attention because of studies that have reported that it is a
highly eﬃcient antioxidant and has free radical scavenging
capacity [4, 15]. Royal jelly is a secretion produced by
the hypopharyngeal and mandibular glands of worker
honeybees (Apis mellifera). It contains many important
compounds with biological activity such as free amino acids,
proteins, sugars, fatty acids, minerals, and vitamins [16]. So
far,RJhasbeendemonstratedtopossessseveralphysiological
activities in experimental animals, including vasodilative
and hypotensive activities [17], the induction of decrease in
serum cholesterol levels [18], antimicrobial [19], antiallergic
[20], anti-inﬂammatory [21], immunomodulatory [22, 23],
and antioxidant properties [16]. In addition, Kanbur et al.
[24] revealed the protective eﬀect of RJ against paracetamol-
induced liver damage in mice.
Apoptosis is a gene-regulated event related to special
morphological changes such as shrinkage of cell, chromatin
condensation, and DNA damages [25]. A number of factors
contributed to apoptotic mechanism, that are believed to
play a key role in two main families of proteins including
cysteine proteases called caspase enzymes (especially caspase
3,8,and9)andBcl-2family.Caspase3,8,and9enzymesplay
an eﬀective role in apoptotic process of the liver and the kid-
ney. Caspase-3, the most important member of caspase fam-
ily,isresponsibleformanybiochemicalmechanismsofapop-
tosis that lead to the cleavage of nuclear and cytosolic sub-
strates,chromatincondensation,fragmentationofDNA,and
apoptoticbodies[26,27].Whereas,Bcl-2,whichisactseither
antiapoptotic (Bcl-xL) or proapoptotic (Bcl-xS), Bcl-xL,a n
important member of this family, prevents apoptotic activity
by blocking cytochrome c release from mitochondria [28].
Thus, the aim of the present study was to investigate the
protective eﬀect of royal jelly in cisplatin-induced oxidative
damages and apoptotic changes of rat liver and kidney by
biochemical and immunohistochemical methods.
2. Results
2.1. Biochemical Findings. No animal death was observed in
the control and other RJ- and CDDP-treated groups. The
eﬀects of RJ and CDDP on serum biochemical parameters
are presented in Table 1. CDDP-treated rats showed a signiﬁ-
cantincreaseinALT,ASTactivities,andcreatininelevels(P<
0.05). However, pretreatment of rats with RJ signiﬁcantly
inhibited these CDDP-induced elevations of ALT and AST
activities and creatinine levels. In addition, RJ alone induced
changes are not signiﬁcant for all biochemical parameters
tested.
The changes in MDA and GSH levels and GSH-Px, GST,
and SOD activities in the liver and kidneys are shown in
Table 2. The MDA levels in the liver and kidneys of animals
thatwereadministeredCDDPalonewereobservedtodisplay
signiﬁcant increase compared with control group, and this
increase was found to be statistically signiﬁcant (P<0.05).
This increase was attenuated by pretreatment with RJ. Also,
signiﬁcantly (P<0.0 5 )r e d u c e dl e v e l so fG S Ha n dG S H - P x ,
GST, and SOD activities were seen in the liver and kidney
tissues of CDDP-treated rats compared with the control
groups. Pretreatment of rats with RJ alleviated these CDDP-
induced decreases (Table 2). Alone RJ treatment resulted in
a signiﬁcant increase in GSH levels and GSH-Px, GST, and
SOD activities accompanied with a signiﬁcant decrease in
MDA compared to the control values.
2.2. Histochemical and Immunohistochemical Findings. The
livers and kidneys of the control and the RJ-only groups
showed normal histological structures. In the CCDP-treated
groups, signiﬁcant histological alterations consisting of con-
gestion, dilatation, epithelial vacuolization, and inﬁltration
of mononuclear cells in both liver and kidney tissues took
place. On the other hand, these changes were decreased in
the RJ + CCDP treated animals.
In this study, apoptotic and antiapoptotic immuneposi-
tive reactions in the liver and kidney were investigated with
caspase-3 and Bcl-xL antibodies, respectively. Comparison
of apoptotic and antiapoptotic activities groups are shownOxidative Medicine and Cellular Longevity 3
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Table 3: Semiquantitative analysis of caspase-3 and Bcl-xL reactiv-
ity in liver and kidney.
Groups
Immunstaining density
Caspase-3 Bcl-xL
Liver Kidney Liver Kidney
C + ++ ++++ ++++
RJ + + ++++ ++++
CCDP ++++ +++ ++ +
RJ + CCDP ++ ++ +++ ++
Caspase-3 and Bcl-xL reaction density was estimated as follows: none: 0,
weak: +, moderate: ++, strong: +++, very strong: ++++. C: Control, RJ:
royal jelly, CDDP: Cisplatin.
in Figures 1, 2, 3,a n d4. Caspase-3 immune reactive cells
were intensely observed around the central vein in the liver
(Figure 1) and proximal tubule epithelium and glomerulus
in kidney of CDDP group (Figure 2). We observed that
the number of apoptotic cells were increased in the liver
and kidneys of CDDP group when compared with other
groups,but,intheRJ+CDDPgroup,thereweresigniﬁcantly
decreased apoptotic cell numbers (P<0.05, Table 3). In
addition, RJ treatment interestingly prevented degenerative
changes and decreased the caspase-3 activity in proximal
tubules according to CDDP groups (Figure 2). Bcl-xL
immune reactive concentration was observed around central
vein in liver (Figure 3) and in cortical tubules, capsula
glomeruli, and podocytes of kidney of the other groups
when compared to CCDP group (Figure 4). On the other
hand, Bcl-xL positive reactions were increased in RJ group
compared to control group (Figures 3 and 4).
3. Discussion
Recent studies suggest that using plant-derived chemo-
preventive agents in combination with chemotherapy can
enhance the eﬃcacy of chemotherapeutic agents and lower
their toxicity to normal tissues [4, 17, 24, 29–31]. This
study investigates the eﬀects of RJ on CDDP-induced liver
and kidney damages. Animals that received CDDP showed
severe biochemical and histological changes in serum and
tissues. On the other hand, pretreatment with RJ caused
a signiﬁcant improvement in tested parameters, which
were signiﬁcantly altered by CDDP administration. Serum
creatinine concentration is commonly used as a measure of
renal function in clinical practice [32]. In our study, Table 1
showstheincreaseinserumcreatinineconcentrations.Inthe
present study, the creatinine concentration of the animals
that were treated by CDDP alone was observed to have
increased. Also accompanying histological ﬁndings show
severe degeneration of cortical tubular cells in the kidney
of CDDP-treated rats. Some authors have also described the
increasing eﬀects of CDDP on creatinine levels and histo-
logical changes [33–35]. In this study, the administration
of RJ before CDDP treatment signiﬁcantly prevented the
increase in serum creatinine level compared to the CDDP
alone treated group. Moreover, histological ﬁndings showed
that RJ administration caused less degenerative alterations in
the liver and kidneys as in previous studies.
The increase in AST and ALT activities in the CDDP-
alone group was found to be related to damage in the liver
and change in hepatic functions. The rise in levels of serum
AST and ALT has been attributed to the damaged structural
integrity of the liver, because these are normally located in
the cytoplasm and are released into the circulation after
hepatic damage [36]. Greggi Antunes et al. [33], Parlakpinar
et al. [34], and Mora et al. [35] have also described the
increasing eﬀects of CDDP on changes in serum AST
and ALT activities. On the other hand, pretreatment with
the RJ remarkably inhibited CDDP-induced liver damage
as evidenced by decreased serum activities of AST and
ALT (Table 1). Additionally, histopathological analysis of
liver sections indicated a moderate centrilobular necrosis
and lymphocytic inﬁltration in rats treated with RJ+CDDP
compared with CDDP alone.
Cisplatin acts on cancer cells by releasing free radicals
such as superoxide radicals, hydroxy radicals, peroxyl rad-
icals, and singlet oxygen, which at the same time damage
liver and kidney cells. Free radicals are known to attack the
highlyunsaturatedfattyacidsofthecellmembranetoinduce
lipidperoxidation,whichisconsideredakeyprocessinmany
pathological events and is one of the reactions induced by
oxidativestress[1,37].Cisplatintreatmentcausesanincrease
in lipid peroxide levels and a decrease in the activities of
antioxidant enzymes that protect against lipid peroxidation
in the tissues such as liver and kidney [31, 38]. Many cellular
pathways have been suggested to contribute to induction of
a state of oxidative stress and lipid peroxides. For example,
it is possible that cisplatin-induced oxidative stress and
cytochrome P450 2E1-(CYP2E1-) mediated oxidative stress
synergize to produce hepatotoxicity [39]. On the other hand,
Saﬁrstein [40] stated that the main targets of cisplatin in
kidney are proximal straight and distal convoluted tubules,
where it accumulates and encourages cellular damage by
multiple mechanisms such as oxidative stress, DNA damage,
and apoptosis.
The present study indicated that lipid peroxidation
(MDA) in liver and kidneys signiﬁcantly increased in rats
treated with cisplatin alone. This result agrees with previ-
ous studies which have demonstrated the involvement of
oxidative stress and lipid peroxidation in CDDP-induced
liver and kidney toxicities [4, 11, 13, 14, 31]. Prophylactic
RJ treatment signiﬁcantly ameliorated the increase in liver
and kidney MDA levels. The RJ contains biologically active
amino acids such as aspartic acid, cysteine, cystine, tyrosine,
glycine, lysine, leucine, valine, and isoleucine. As indicated
by previous researchers, the antioxidant eﬀect of RJ may be
related to its free amino acid content [41].
Reactive oxygen species (ROS) such as hydrogen perox-
ide, superoxide anions, and hydroxyl radicals are generated
under normal cellular conditions and are immediately
detoxiﬁed by major scavenger enzymes (glutathione based
enzymes such as GSH-Px, GST, SOD, and CAT. However,
excessive ROS production by CDDP causes antioxidant
imbalance and leads to lipid peroxidation and antioxidant
depletion [42]. In our study, the major scavenger enzymes
activities (GSH, GSH-Px, GST, and SOD) were signiﬁcantly
decreased in liver and kidneys of cisplatin-treated rats. ThisOxidative Medicine and Cellular Longevity 5
(a) (b)
(c) (d)
Figure 1: Caspase-3 positive reactions in rat livers. (a) Control, (b) RJ, (c) CDDP, (d) RJ + CDDP (streptavidin-biotin peroxidase staining),
bar 20µm.
(a) (b)
(c) (d)
Figure2:Caspase-3positivereactionsinratkidneys.(a)Control,(b)RJ,(c)CDDP,(d)RJ+CDDP(streptavidin-biotinperoxidasestaining),
bar 20µm.6 Oxidative Medicine and Cellular Longevity
(a) (b)
(c) (d)
Figure 3: Bcl-xL positive reactions in rat livers. (a) Control, (b) RJ, (c) CDDP, (d) RJ + CDDP (streptavidin-biotin peroxidase staining), bar
20µm.
(a) (b)
(c) (d)
Figure 4: Bcl-xL positive reactions in rat kidneys. (a) Control, (b) RJ, (c) CDDP, (d) RJ + CDDP (streptavidin-biotin peroxidase staining),
bar 20µm.Oxidative Medicine and Cellular Longevity 7
result may be connected with the CDDP-induced increase in
freeradicalgenerationoradecreaseinamountsofprotecting
enzymes against lipid peroxidation. In previous studies,
CDDP has been found to have a peroxidative eﬀect on the
liver and kidney tissues [4, 14, 34]. However, the treatment
with RJ ameliorated the cisplatin-induced liver and kidney
damages due to free radical production. Meanwhile, the
elevated GSH level, activities of GSH-Px, GST, and SOD
enzymes in the CDDP plus RJ group implied a decrease in
the number of free radicals after cisplatin administration
and reﬂected that these enzymes played important roles
in scavenging of free radical. Our ﬁndings are similar
to results of other investigators such as Al-Majed et al.
[43], Aleisa et al. [44], and Arafa [30] for kidney and
liver tissues in which cisplatin and carboplatin injections
caused low GSH, GSH-Px, SOD, and nitric oxide levels.
Furthermore, in this study, it was observed that levels of
GSH, activities of GST, GSH-Px, and SOD in CDDP plus
RJ-treated group were higher than in the CDDP group.
These results suggested that RJ has a supporting eﬀect on
theantioxidantsystembecauseofincreasesinGSH,GSH-Px,
GST, and SOD activities. Recently, it has been demonstrated
that RJ prevents carbon tetrachloride- [15], cadmium- [45],
andparacetamol-[24]inducedlivertoxicitygenotoxicityand
nephrotoxicity, respectively.
A number of studies reported that CDDP has been found
to have an apoptotic eﬀect on kidney and liver [28, 46–48].
Apoptosis is characterized by phosphatidylserine external-
ization, membrane budding, cell shrinkage, and chromatin
condensation. The apoptotic caspase enzymes are named
as initiator caspases (e.g., 2, 8, 9, 10 and 12) and eﬀector
caspases (e.g., 3, 6, and 7). The eﬀector caspases act via the
activation of initiator caspases which trigger the apoptotic
process [26, 27, 49], whereas Bcl-2 family proteins, which
are generally acts antiapoptotic, are inhibited cytochrome
c release from mitochondria and programmed cell death-
inducingenzymes[28,50,51].Bcl-xL isamemberoftheBcl-
2 family, which has been observed to regulate apoptosis in
response to chemotherapy [51, 52]. Bcl-xL may be inhibiting
apoptotic process by forming an inhibitory complex with
procaspase-9 and Apaf-1, whose overexpressions are delay
or inhibit apoptosis [53], as well as provide a true survival
advantage in cell treated with chemotherapeutic agents [51].
In this study, an increased immune positive staining of Bcl-
xL were observed in both liver and kidney sections in RJ +
CCDP compared to CCDP group. These ﬁndings suggested
that the overexpression pattern of the Bcl-xL family protein
caused by royal jelly might be required in chemotherapy.
Caspase-3 has been identiﬁed as being a key mediator
of apoptosis in mammalian cells. Apoptosis is caused by
activation of the initiator caspases-8 and caspase-9, which
trigger the eﬀector caspase-3 [54] .R e n a lc e l ld e a t hi sa
consequence of cisplatin treatment during chemotherapy
and is one of the major factors limiting its use [47, 55].
In the proximal tubules of cisplatin-treated kidneys may be
showed histological changes such as apoptosis and oncosis
[49]. This is similar to results with cisplatin in vitro where
apoptosis or oncosis is dependent on the concentration
and length of exposure [56]. In vitro, caspase-3 is activated
during cisplatin-induced renal cell apoptosis [56], but the
mechanismsresponsibleforcaspase-3activationarenotfully
understood. In this study, an increased caspase-3 expression
was observed liver and kidneys of rats treated with CCDP
compared to control group. This results of this study were
in agreement with those of the previous reports [29, 48, 57].
The cisplatin-induced apoptosis is believed to be the result
of DNA damage [46, 47]. These results demonstrate that the
caspase-3 activity increase might be correlated with CCDP-
induced apoptosis. Besides, RJ pretreatment before CCDP
injectioninbothliverandkidneyloweredapoptoticimmune
staining cell numbers but increased antiapoptotic Bcl-xL
activity. Therefore, cisplatin-induced apoptosis, at least in
part, may be prevented by royal jelly.
4. Conclusion
In conclusion, CDDP treatment induces liver and kidney
injury as indicated by the elevation of serum biochemical
parameters, the decline of the antioxidant activity, and
the increases of caspase-3 immune staining cells number.
T h ee x c e s s i v ep r o d u c t i o no ff r e er a d i c a l si so n eo ft h e
main reasons for the changes above. However, pretreatment
with RJ was found to reduce the CDDP-induced liver and
kidney chemical changes and apoptotic cell numbers. This
protectionmaybeduetoantiapoptotic,antioxidant,andfree
radical scavenging activity of royal jelly and its components.
Therefore, RJ may be of help to prevent liver and kidney
toxicity manifested by CDDP chemotherapy.
5.MaterialandMethods
5.1. Materials. Royal jelly was obtained from Arı M¨ uhen-
dislik Company, Ankara, Turkey, and was stored at −20◦C
until used. Doses of 300mg/kg RJ were dissolved in distilled
water and given orally for 10 consecutive days to groups
of RJ and RJ + CDDP rats. The injectable form of CDDP
(Ebewe and Liba, Istanbul, Turkey) was purchased from
local pharmacies. All other chemicals were obtained from
Sigma (St. Louis, Mo, USA).
5.2. Animals and Treatments. The Atat¨ urk University’s Ex-
perimental Research Centre, Erzurum, Turkey, provided
adult female Sprague Dawley rats, 180±20g, and 6–8 weeks
old. The animals were kept in metal cages at a temperature of
22–24◦C and a 12-hour light/dark cycle during the study and
were fed with standard commercial rat food and tap water.
All experiments in this study were approved by the Local
Ethics Board of Animal Experiments in Atat¨ urk University.
The animals were divided into 4 groups, each with 6 rats,
according to their experimental treatment. Control group
rats (C) received 0.9% saline. Royal jelly group rats (RJ)
were treated for 15 consecutive days by gavage with RJ
(300mg/kg/day). Cisplatin group rats (CDDP) received a
single-dose injection of CDDP (7mg/kg body weight i.p.;
Ebewe and Liba, Istanbul, Turkey) all at once. Royal jelly plus
cisplatin group rats (RJ + CDDP) received single oral doses
of royal jelly (300mg/kg/day p.o.) for 15 consecutive days
following a single-dose i.p. injection of CDDP (7mg/kg−1).8 Oxidative Medicine and Cellular Longevity
5.3. Sample Collection and Biochemical Assays. Twenty-four
hours after the ﬁnal RJ and CDDP treatments, all animals
were anaesthetized with an i.p. injection of 60mg sodium
pentobarbitone per kg body weight and then sacriﬁced by
cervical dislocation. Blood samples were collected into tubes
and centrifuged at 3000g for 10min. Sera were separated
and then stored at −80◦C until analysed. The liver and
kidneys were removed, washed with physiological saline
solution, and stored at −80◦C until analysis. All tissues were
maintained at +4◦C throughout preparation. A portion of
liver and kidneys (1:9, w/v) for all assays were homogenized
in a 0.9% NaCl solution with an OMNI TH international
homogenizer (Warrenton, Va, USA). Tissue homogenates
were centrifuged for 15 minutes at 15.000g, and then
the clear supernatants were removed for analyses. For the
measurement of malondialdehyde (MDA) levels, the method
described by Ohkawa et al. [58]w a su s e d .M e a s u r e m e n t so f
tissue glutathione (GSH), glutathione-peroxidase (GSH-Px),
glutathione-S-transferase (GST), and superoxide dismutase
(SOD) activities were performed in accordance with the
methods described by Tietze [59]a n dA n d e r s o n[ 60], Paglia
and Valentine [61], Habig et al. [62], and Sun et al. [63],
respectively. The results were expressed as nmol/g protein for
MDA, µmol/g protein for GSH and GST, and U/g protein
for GSH-Px and SOD. Alanine aminotransferase (ALT) and
aspartate aminotransferase (AST) activities and creatinine
concentration were measured by using auto analyser (AU-
2700; Olympus, Tokyo, Japan).
5.4. Histochemical and Immunohistochemical Examination.
The liver and kidney samples were ﬁxed in 10% buﬀered
neutral formalin and embedded in paraﬃn. The paraﬃn
blocks were cut 5–7µm thick and stained with Mal-
lory’s triple stain modiﬁed by Crossman. Stained speci-
mens were examined under a light microscope. Apoptotic
cells were determined by immunohistochemical method
(streptavidin-biotin-peroxidase staining) seen as brown
colour. For immunohistochemical examination, primary
antibodies monoclonal caspase-3 (dilution: 1/25, Biovision-
3015-100) and Bcl-xL (dilution: 1/50 Santa cruz-sc-8392)
and biotinylated secondary antibody (DAKO-Universal
LSAB Kit-K0690) were used. The binding sites of anti-
body were visualized with DAB (Sigma) and evaluated
by high-power light microscopic examination (Nikon i50).
All apoptotic and antiapoptotic staining cells were esti-
mated with an image processing system (Kameram SLR,
1.6.1.0, Mikro Sistem Ltd. S ¸ti., Turkey). For each speci-
men, caspase-3 and Bcl-xL immunreactivities were exam-
ined in 10 randomly selected areas of approximately X20
objective.
The microscopic scoring of sections was carried out
by a histopathology laboratory technician and histologist.
This scale has composed to A:w e a ki n≤25% of tissue; B:
mild in ≤50% of tissue; C:m o d e r a t ei n≤75% of tissue; D:
very strong in ≥75% of tissue. The average degeneration
intensity was calculated as ((A×1)+(B×2)+(C×3)+(D×
4))/(A + B + C + D) and reported as follows: + = 0.00–1.00;
++ = 1.01–2.00; +++ = 2.01–3.00; ++++ = 3.01–4.00.
The scores were derived semiquantitatively using light
microscopy on the preparations from each animal and were
reported as follows: none: −, mild: +, moderate: ++, severe:
+++, and very strong: ++++.
5.5. Statistical Analysis. For statistical analysis, diﬀerences
between the groups were tested by the analysis of variance
(ANOVA) followed by Duncan’s post hoc test using SPSS
17.0 for Windows XP (SPSS Inc., Chicago, Ill). A value P<
0.05 was considered signiﬁcant. All data were expressed as
mean averages, ± S.E.M.
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